Device Trial Radar · NCT04659213
Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation - EASY AF STUDY
Last checked: Nov 19, 2026Latest source record: Oct 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Sep 1, 2021
Primary completion
Jun 30, 2022
Study completion Jul 31, 2022
Sponsor
- Lead sponsor
- S4 MedicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess if deviating the esophagus will reduce/eliminate ablation injury to the esophagus.
Conditions
- Atrial Fibrillation
Interventions
esolution catheterDevice
esolution is a catheter-based therapy designed to displace the esophagus away from the source of ablation energy during ablation of AF and to eliminate the risk of esophageal injury
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of esophageal injury attributable to RF ablation energy as noted on post ablation endoscopyTime frame: 15-72 hours post-ablation procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
OSU
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.